NCT06047145已完成不适用
Evaluation of Oral Soy Isoflavone Concentrates on Skin Ageing Parameters: a Double-blind Randomised Placebo-controlled Trial
The Archer-Daniels-Midland Company1 个研究点 分布在 1 个国家目标入组 66 人开始时间: 2023年10月27日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 66
- 试验地点
- 1
- 主要终点
- Change in Crow's Feet wrinkles (Ra)
研究概览
简要总结
This double-blind, placebo-controlled, randomised pilot trial aims to assess the effect of oral soy isoflavone consumption on skin ageing parameters in post-menopausal women.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Healthy subject.
- •Sex: female.
- •Age: from 40 to 65 years (inclusive).
- •Phototype: I to IV on the Fitzpatrick scale.
- •Post-menopausal subject, with last menstrual period at least 12 months prior to screening and who is not using hormonal contraception.
- •Subject having Crow's feet wrinkles from grade 2 to 5 on Bazin's scale.
- •Subject having under eyes wrinkles.
- •Subject agreeing not to change her alimentary and cosmetic habits during the study.
- •Subject, able to understand the study related information and to give a written informed consent.
- •Subject having given freely and expressly informed consent.
- •Subject able and willing to comply with protocol requirements.
- •Subject affiliated to a health social security system.
排除标准
- •Women with childbearing potential or women on long term hormonal contraception whose childbearing potential is difficult to ascertain.
- •Subject deprived of her freedom by administrative or legal decision.
- •Subject under guardianship or unable to provide consent.
- •Subject in a social or healthcare institution.
- •Subject suspected to be non-compliant according to the investigator's judgment.
- •Subject participating in any other clinical study or being in an exclusion period for a previous study.
- •Subject having crow's feet wrinkles with grades < 2 or > 5 on Bazin's scale.
- •Subject with a tattoo, a scar, moles, too many hairs or anything on the studied zones which might interfere with the evaluation.
- •Personal or family history of breast, uterine or ovarian cancer as per investigator judgement.
- •Subject with personal history of cancer.
- •Subject with a condition or receiving a medication which, in the investigator's judgement, put the subject at undue risk.
- •Subject suffering from a severe or progressive disease, likely to interfere with the measured parameters.
- •Subject with any skin or systemic disease (acute and/or chronic), ongoing or in the previous year, likely to interfere with the measured parameters or to put the subject at undue risk.
- •Subject with known history of or suffering from autoimmune disease and/or immune deficiency.
- •Subject with allergies or intolerance to soy or soy products.
- •Subject having history of allergy or hypersensitivity to any of the components of the tested product.
- •Subject under anti-coagulant treatment.
- •Subject under thyroid hormones treatment.
- •Subject under osteoporosis treatment other than vitamin D and calcium.
- •Subject having started or stopped supplements used to treat menopausal symptoms, which may affect measured parameters, such as phytoestrogens, Black Cohosh, dehydroepiandrosterone (DHEA), hyaluronic acid, collagen, NADH, resveratrol soy supplements, etc. within one month prior to screening.
- •Subject having received injection with botulinum toxin on Crow's feet wrinkles in the year before the screening visit.
- •Subject having received injection with botulinum toxin on other zone of the face in the past 6 months before the screening visit.
- •Subject having received injection of filling product on the studied zones (crow's feet and under eye wrinkles, cheekbones and forearms) in the year before the screening visit.
- •Subject having received tensor threads on the face in the two years before the screening visit.
- •Subject having received injection of mesotherapy in the face in the past 3 months before the screening visit.
- •Subject having received professional peeling on the face and forearms in the past 3 months before the screening visit.
- •Subject having received a treatment with a laser on the face or forearms in the past 6 months before the screening visit.
- •Subject under oral hormonal substitutive treatment during the year previous the screening visit.
- •Subject receiving any long-term medical treatment or any treatment that, in the opinion of the clinical investigator, may interfere with test results or put the subject at undue risk.
- •Subject undergoing a topical treatment on the test area (forearms and face) or a systemic treatment:
- •corticosteroids during the 2 previous weeks and during the study.
- •retinoids and/or immunosuppressors during the 3 previous months and during the study.
- •Intensive exposure to sunlight within the previous month and foreseen during the study without adequate sun protection, as per the investigator's judgement.
- •Exposure to artificial UV or spray tan in the month preceding the screening or during the study.
- •Subject with an excessive consumption of alcohol (more than 2 glasses of wine per day) and/or tobacco (more than 10 cigarettes per day).
研究组 & 干预措施
placebo
Placebo Comparator
One oral capsule daily containing equivalent placebo for 84 days
干预措施: Placebo (Dietary Supplement)
结局指标
主要结局
Change in Crow's Feet wrinkles (Ra)
时间窗: day 0, day 84
Cutaneous relief parameters (Ra - Average roughness) on Crow's Feet wrinkles measured with fringe projection acquisitions
次要结局
- Change in Crow's Feet wrinkles (Rt)(day 0, day 42, day 84)
- Change in under eye wrinkles (Ra)(day 0, day 42, day 84)
- Change in skin colour(day 0, day 42, day 84)
- Change in skin barrier function(day 0, day 42, day 84)
- Change in under eye wrinkles (Rz)(day 0, day 42, day 84)
- Change in skin hydration(day 0, day 42, day 84)
- Change in Crow's Feet wrinkles (Ra)(day 0, day 42)
- Change in Crow's Feet wrinkles (Rz)(day 0, day 42, day 84)
- Change in under eye wrinkles (Rt)(day 0, day 42, day 84)
- Subject satisfaction(day 42, day 84)
- Adverse events(day 0, day 42, day 84)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Effect of supplementation in treatment of women with polycystic ovary syndromePolycystic ovary syndrome.Polycystic ovarian syndromeIRCT201604015623N70Vice chancellor for research, Kashan University of Medical Sciences70
已完成
3 期
Effect of supplementation in treatment of women with polycystic ovary syndromePolycystic ovary syndrome.Polycystic ovarian syndromeE28.2IRCT201601025623N62Vice chancellor for research, Arak University of Medical Sciences70
已完成
不适用
The Effects of Soy Protein and Isoflavones on Glycemic Control, Insulin Sensitivity and Cardiovascular Risk FactorsCardiovascular RiskDiabetesNCT00856882Chinese University of Hong Kong
已完成
2 期
Examination of a Soy-Based Supplement for Major DepressionDepressionNCT00042380National Institute of Mental Health (NIMH)120
已完成
2 期
Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing SurgeryRecurrent Hypopharyngeal Squamous Cell CarcinomaRecurrent Laryngeal Squamous Cell CarcinomaRecurrent Laryngeal Verrucous CarcinomaRecurrent Lip and Oral Cavity Squamous Cell CarcinomaRecurrent Oral Cavity Verrucous CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaStage I Hypopharyngeal Squamous Cell CarcinomaStage I Laryngeal Squamous Cell CarcinomaStage I Laryngeal Verrucous CarcinomaStage I Lip and Oral Cavity Squamous Cell CarcinomaStage I Oral Cavity Verrucous CarcinomaStage I Oropharyngeal Squamous Cell CarcinomaStage II Hypopharyngeal Squamous Cell CarcinomaStage II Laryngeal Squamous Cell CarcinomaStage II Laryngeal Verrucous CarcinomaStage II Lip and Oral Cavity Squamous Cell CarcinomaStage II Oral Cavity Verrucous CarcinomaStage II Oropharyngeal Squamous Cell CarcinomaStage III Hypopharyngeal Squamous Cell CarcinomaStage III Laryngeal Squamous Cell CarcinomaStage III Laryngeal Verrucous CarcinomaStage III Lip and Oral Cavity Squamous Cell CarcinomaStage III Oral Cavity Verrucous CarcinomaStage III Oropharyngeal Squamous Cell CarcinomaStage IV Hypopharyngeal Squamous Cell CarcinomaStage IVA Laryngeal Squamous Cell CarcinomaStage IVA Laryngeal Verrucous CarcinomaStage IVA Lip and Oral Cavity Squamous Cell CarcinomaStage IVA Oral Cavity Verrucous CarcinomaStage IVA Oropharyngeal Squamous Cell CarcinomaTongue CarcinomaNCT02007200National Cancer Institute (NCI)55